DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the market capitalisation of Parmax Pharma Ltd?

Parmax Pharma Ltd has a market capitalisation of approximately ₹39 crore.

Parmax Pharma Ltd

540359·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

Mkt Cap₹39 Cr

P/E—

Vol—

Day—

52W23–109

Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

O—H—L—PC—VWAP—VOL—

52W₹22.60

₹109.20

Snapshot

Key stats

Mkt Cap

₹39 Cr

P/E

N/A

P/B

-5.72

ROE

105.30%Strong

ROCE

-12.45%Weak

52W High / Low

₹109 / ₹23

Div Yield

0.00%

EPS

₹-5.59

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

105.3%Strong

Above 15% is considered healthy for Indian equities

ROCE

-12.4%Weak

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹39 Cr

P/B

-5.72

EPS

₹-5.59

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-7.7%

-14.3%

10Y

—

Profit

—

10Y

—

EPS

—

10Y

—

Profile

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of -14.3% over past five years.
Promoter holding is low: 30.8%
Debtor days have increased from 57.4 to 95.2 days.

More Healthcare stocks · Pharmaceuticals

Explore Parmax Pharma Ltd’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.